Ind-Swift Laboratories Ltd
Add to watch list to get report alerts
BSE Code:
532305
NSE Code:
INDSWFTLAB
Business Profile
Business Profile
Incorporated in 1995, Chandigarh, India-based Ind-Swift Laboratories (ISL) is a part of the Ind-Swift group. The company is promoted and managed by Ind-Swift in joint venture with Punjab State Industrial Development Corporation. Manufacturing units of ISL are located in Punjab and Jammu. Ind Swift Laboratories, a wholly owned subsidiary of ISL, was incorporated in the USA in Mar. 2004.
It manufactures a wide range of solid, liquid, semi liquid forms, capsule, tablets, dry/liquid injectable eye/ear drops, oral solution, and creams/gels. The company`s products include Clarithromycin, Fexofenadine, Clarie granules, Pentazocine, Roxithromycin, Clopidogrel, Azithromycin, and Atorvastatin. Its products are used in the macrolide antibiotic, antiallergy, cardiovascular, diabetology, and antiulcerant therapeutic sector.
ISL has emerged as an efficient supplier of bulk-actives in more than 45 countries. The services of the company includes research for active pharmaceuticals intermediaries / advanced intermediates, development of non-infringing processes for promising molecules, process optimization and improvement, contract research, contract manufacturing, etc.
Financials
Ind-Swift Laboratories registered a 25.96% growth in net profits to Rs 53.33 million for the quarter ended in June 2007 from a profit of Rs 42.34 million for the quarter ended in June 2006Net Sales quarter rose 89.60% to Rs 1004.27 million for the quarter ended June 2007 from Rs 529.69 million for the quarter ended June 2006.Total income rose 85.87% to Rs 1034.8 million for the quarter ended June 2007, from Rs 556.74 million for the quarter ended June 2006.The earnings per share (EPS) of the company stood at Rs 2.34 in the quarter ended June 2007 .
Recent Developments
08-FEB-07
Ind Swift Laboratories has announced that the Company has received the USFDA approval for its API manufacturing faculty situated at Village Bhagwanpur, Derabassi. This facility has already received the COS and TGA certifications. The Company is also at an advanced stage of launching its drugs in the Japanese Markets
28-MAR-06
The company receives the European Directorate for the quality of medicines certification for its key bulk drug Clarithromycin.
Future Plans
The company is working with leading players for contract research in Europe. Under contract research and manufacturing plans, they are negotiating with US companies through their US subsidiary for long term agreements. ISL is planning to receive 60% of the exports revenues from the regulated markets by the year 2008. The company is planning to launch 20 new products within next three years. The company plans to expand their production facility in the segment of Oncology, Macrolide, Antibiotics, CNS and Sate-of-the-art R & D Centre with pilot production facilities.